We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

2 hedge funds and large institutions have $4.21K invested in Eagle Pharmaceuticals, Inc. in 2026 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

51% less capital invested

Capital invested by funds: $8.64K → $4.21K (-$4.43K)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
SLG
1
Stanley-Laman Group
Pennsylvania
$4.09K – – –
AIC
2
Archer Investment Corporation
Indiana
$119 – – –

EGRX Hedge Fund Activity: Q1 2026 in Review

2 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q1 2026, worth a combined $4.21K — down 51% from $8.64K a quarter earlier.

Fund positioning in EGRX was balanced in Q1 2026: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 2 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q1 2026, unchanged from Q4 2025.
  • Funds reported $4.21K of Eagle Pharmaceuticals, Inc. stock for Q1 2026, down 51% quarter-over-quarter.
  • 0 funds opened new Eagle Pharmaceuticals, Inc. positions in Q1 2026 and 0 closed out.

Based on aggregated 13F filings for Q1 2026.